Conditions: Gout
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 31
Healthy volunteers: no

Brief summary:
This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.

Detailed description:

Arms:
arm 1: RDEA3170 15 mg once daily fasted arm 2: RDEA3170 15 mg once daily fasted arm 3: RDEA3170 15 mg once daily fasted arm 4: RDEA3170 15 mg once daily fasted

Interventions: intervention 1: RDEA3170
Intervention descriptions: intervention 1: None

Protocol document: